That is true. I bet something else is just not mentioned in the article. Maybe they are still unsure which doses to test. Or how to give it to patient and while Phase 1 answers some of these questions the FDA will want approximate answes before they would approve clinical trials especially with a new drug where they may not have seen the active ingredient before.
That is true. I bet something else is just not mentioned in the article. Maybe they are still unsure which doses to test. Or how to give it to patient and while Phase 1 answers some of these questions the FDA will want approximate answes before they would approve clinical trials especially with a new drug where they may not have seen the active ingredient before.
Yeah, I responded that I would have expected some of that to have been done in this section of research, just not published in this article.